Phase Behavior of Poly(vinylpyrrolidone) Containing Amorphous Solid Dispersions in the Presence of Moisture
The objective of this study was to investigate the phase behavior of amorphous solid dispersions composed of a hydrophobic drug and a hydrophilic polymer following exposure to elevated relative humidity. Infrared (IR) spectroscopy, differential scanning calorimetry (DSC) and moisture sorption analys...
Saved in:
Published in: | Molecular pharmaceutics Vol. 6; no. 5; pp. 1492 - 1505 |
---|---|
Main Authors: | , , , |
Format: | Journal Article |
Language: | English |
Published: |
United States
American Chemical Society
05-10-2009
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | The objective of this study was to investigate the phase behavior of amorphous solid dispersions composed of a hydrophobic drug and a hydrophilic polymer following exposure to elevated relative humidity. Infrared (IR) spectroscopy, differential scanning calorimetry (DSC) and moisture sorption analysis were performed on five model systems (nifedipine−poly(vinylpyrrolidone) (PVP), indomethacin−PVP, ketoprofen−PVP, droperidol−PVP, and pimozide−PVP) immediately after production of the amorphous solid dispersions and following storage at room temperature and elevated relative humidity. Complete miscibility between the drug and the polymer immediately after solid dispersion formation was confirmed by the presence of specific drug−polymer interactions and a single glass transition (T g) event. Following storage at elevated relative humidity (75−94% RH), nifedipine−PVP, droperidol−PVP, and pimozide−PVP dispersions formed drug-rich and polymer-rich amorphous phases prior to crystallization of the drug, while indomethacin−PVP and ketoprofen−PVP dispersions did not. Drug crystallization in systems exhibiting amorphous−amorphous phase separation initiated earlier (<6 days at 94% RH) when compared to systems that remained miscible (≥46 days at 94% RH). Evidence of moisture-induced amorphous−amorphous phase separation was observed following storage at as low as 54% RH for the pimozide−PVP system. It was concluded that, when an amorphous molecular level solid dispersion containing a hydrophobic drug and hydrophilic polymer is subjected to moisture, drug crystallization can occur via one of two routes: crystallization from the plasticized one-phase solid dispersion, or crystallization from a plasticized drug-rich amorphous phase in a two-phase solid dispersion. In the former case, the polymer is still present in the same phase as the drug, and can inhibit crystallization to a greater extent than the latter scenario, where the polymer concentration in the drug phase is reduced as a result of the amorphous−amorphous phase separation. The strength of drug−polymer interactions appears to be important in influencing the phase behavior. |
---|---|
AbstractList | The objective of this study was to investigate the phase behavior of amorphous solid dispersions composed of a hydrophobic drug and a hydrophilic polymer following exposure to elevated relative humidity. Infrared (IR) spectroscopy, differential scanning calorimetry (DSC) and moisture sorption analysis were performed on five model systems (nifedipine-poly(vinylpyrrolidone) (PVP), indomethacin-PVP, ketoprofen-PVP, droperidol-PVP, and pimozide-PVP) immediately after production of the amorphous solid dispersions and following storage at room temperature and elevated relative humidity. Complete miscibility between the drug and the polymer immediately after solid dispersion formation was confirmed by the presence of specific drug-polymer interactions and a single glass transition (T(g)) event. Following storage at elevated relative humidity (75-94% RH), nifedipine-PVP, droperidol-PVP, and pimozide-PVP dispersions formed drug-rich and polymer-rich amorphous phases prior to crystallization of the drug, while indomethacin-PVP and ketoprofen-PVP dispersions did not. Drug crystallization in systems exhibiting amorphous-amorphous phase separation initiated earlier (<6 days at 94% RH) when compared to systems that remained miscible (>or=46 days at 94% RH). Evidence of moisture-induced amorphous-amorphous phase separation was observed following storage at as low as 54% RH for the pimozide-PVP system. It was concluded that, when an amorphous molecular level solid dispersion containing a hydrophobic drug and hydrophilic polymer is subjected to moisture, drug crystallization can occur via one of two routes: crystallization from the plasticized one-phase solid dispersion, or crystallization from a plasticized drug-rich amorphous phase in a two-phase solid dispersion. In the former case, the polymer is still present in the same phase as the drug, and can inhibit crystallization to a greater extent than the latter scenario, where the polymer concentration in the drug phase is reduced as a result of the amorphous-amorphous phase separation. The strength of drug-polymer interactions appears to be important in influencing the phase behavior. The objective of this study was to investigate the phase behavior of amorphous solid dispersions composed of a hydrophobic drug and a hydrophilic polymer following exposure to elevated relative humidity. Infrared (IR) spectroscopy, differential scanning calorimetry (DSC) and moisture sorption analysis were performed on five model systems (nifedipine−poly(vinylpyrrolidone) (PVP), indomethacin−PVP, ketoprofen−PVP, droperidol−PVP, and pimozide−PVP) immediately after production of the amorphous solid dispersions and following storage at room temperature and elevated relative humidity. Complete miscibility between the drug and the polymer immediately after solid dispersion formation was confirmed by the presence of specific drug−polymer interactions and a single glass transition (T g) event. Following storage at elevated relative humidity (75−94% RH), nifedipine−PVP, droperidol−PVP, and pimozide−PVP dispersions formed drug-rich and polymer-rich amorphous phases prior to crystallization of the drug, while indomethacin−PVP and ketoprofen−PVP dispersions did not. Drug crystallization in systems exhibiting amorphous−amorphous phase separation initiated earlier (<6 days at 94% RH) when compared to systems that remained miscible (≥46 days at 94% RH). Evidence of moisture-induced amorphous−amorphous phase separation was observed following storage at as low as 54% RH for the pimozide−PVP system. It was concluded that, when an amorphous molecular level solid dispersion containing a hydrophobic drug and hydrophilic polymer is subjected to moisture, drug crystallization can occur via one of two routes: crystallization from the plasticized one-phase solid dispersion, or crystallization from a plasticized drug-rich amorphous phase in a two-phase solid dispersion. In the former case, the polymer is still present in the same phase as the drug, and can inhibit crystallization to a greater extent than the latter scenario, where the polymer concentration in the drug phase is reduced as a result of the amorphous−amorphous phase separation. The strength of drug−polymer interactions appears to be important in influencing the phase behavior. |
Author | Taylor, Lynne S Stanford, Lindsay A Marsac, Patrick J Rumondor, Alfred C. F |
Author_xml | – sequence: 1 givenname: Alfred C. F surname: Rumondor fullname: Rumondor, Alfred C. F – sequence: 2 givenname: Patrick J surname: Marsac fullname: Marsac, Patrick J – sequence: 3 givenname: Lindsay A surname: Stanford fullname: Stanford, Lindsay A – sequence: 4 givenname: Lynne S surname: Taylor fullname: Taylor, Lynne S email: ltaylor@pharmacy.purdue.edu |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/19634917$$D View this record in MEDLINE/PubMed |
BookMark | eNptkEtPwzAQhC1URB9w4A8gX5DoIWDHcRIfS3lKRVQCzpHj2MQlsSM7qZR_T6pW5cJpVtpPszszBSNjjQTgEqNbjEJ8VzcMIUSROAETTCMSpISFo-OcRmMw9X6DUBjRkJyBMWYxiRhOJuBnXXIv4b0s-VZbB62Ca1v1N1tt-qrpnbOVLoZrc7i0puXaaPMNF7V1TWk7Dz92a_igfSOd19Z4qA1sSwnXTnpphNwZvlnt287Jc3CqeOXlxUFn4Ovp8XP5Eqzen1-Xi1XASYragDKVsoTEhRgUD7mYyhVRJGEiiRGLCprmqlC5SDESRPKcSFXIKI8pprGIKZmB-d5XOOu9kyprnK656zOMsl1h2bGwgb3as02X17L4Iw8NDcD1HuDCZxvbOTO8_o_RL3pFdbw |
CitedBy_id | crossref_primary_10_1016_j_ijpharm_2013_07_030 crossref_primary_10_1021_acs_cgd_6b01901 crossref_primary_10_1146_annurev_chembioeng_060718_030304 crossref_primary_10_1002_jps_22247 crossref_primary_10_1021_acs_molpharmaceut_6b00866 crossref_primary_10_1021_mp300423r crossref_primary_10_3390_polym13172922 crossref_primary_10_1007_s12247_012_9121_2 crossref_primary_10_1016_j_matpr_2019_03_171 crossref_primary_10_1016_j_xphs_2016_06_017 crossref_primary_10_1021_mp300079x crossref_primary_10_1016_j_xphs_2021_10_016 crossref_primary_10_1080_17425247_2016_1198769 crossref_primary_10_1002_jps_24261 crossref_primary_10_1021_acs_molpharmaceut_6b01151 crossref_primary_10_1016_j_ejps_2019_105057 crossref_primary_10_1016_j_xphs_2022_09_013 crossref_primary_10_1021_acs_molpharmaceut_5b00925 crossref_primary_10_1007_s11095_022_03183_4 crossref_primary_10_1021_acs_molpharmaceut_9b01272 crossref_primary_10_1016_j_ijpharm_2023_123490 crossref_primary_10_1016_j_xphs_2020_09_016 crossref_primary_10_1007_s11095_012_0689_5 crossref_primary_10_1016_j_xphs_2018_02_008 crossref_primary_10_1021_acs_molpharmaceut_1c00972 crossref_primary_10_3109_10837450_2013_775157 crossref_primary_10_1016_j_carbpol_2012_10_051 crossref_primary_10_1002_jps_23966 crossref_primary_10_3109_03639045_2011_558091 crossref_primary_10_1016_j_xphs_2019_10_010 crossref_primary_10_3390_ijms25052774 crossref_primary_10_1111_jphp_12145 crossref_primary_10_3109_03639045_2015_1054400 crossref_primary_10_1007_s11095_017_2254_8 crossref_primary_10_1021_acs_molpharmaceut_9b00731 crossref_primary_10_1021_acs_molpharmaceut_9b01025 crossref_primary_10_1016_j_addr_2016_03_006 crossref_primary_10_1002_jps_23957 crossref_primary_10_1208_s12249_019_1562_1 crossref_primary_10_1021_mp100013p crossref_primary_10_3109_03639045_2013_767825 crossref_primary_10_1016_j_ijpharm_2017_07_034 crossref_primary_10_1016_j_ejps_2018_07_007 crossref_primary_10_1016_j_ijpharm_2010_08_013 crossref_primary_10_3390_pharmaceutics13071074 crossref_primary_10_1016_j_xphs_2024_05_014 crossref_primary_10_1021_jp3106716 crossref_primary_10_1021_acs_molpharmaceut_7b00492 crossref_primary_10_1021_mp9002283 crossref_primary_10_1021_mp100205g crossref_primary_10_1016_j_ijpharm_2020_119292 crossref_primary_10_1016_j_xphs_2017_10_028 crossref_primary_10_1016_j_xphs_2023_08_021 crossref_primary_10_1002_jps_22462 crossref_primary_10_1002_jps_22583 crossref_primary_10_3390_pharmaceutics13101682 crossref_primary_10_1021_acs_molpharmaceut_1c00519 crossref_primary_10_1021_acs_molpharmaceut_5b00705 crossref_primary_10_3109_03639045_2013_828216 crossref_primary_10_1007_s11095_021_03147_0 crossref_primary_10_1016_j_xphs_2022_07_020 crossref_primary_10_1016_j_jddst_2018_05_016 crossref_primary_10_1002_aic_14979 crossref_primary_10_1021_acs_molpharmaceut_0c00467 crossref_primary_10_1021_mp1003674 crossref_primary_10_3390_pharmaceutics13111857 crossref_primary_10_1016_j_ijpharm_2021_120637 crossref_primary_10_1021_acs_molpharmaceut_5b00041 crossref_primary_10_1016_j_xphs_2016_08_017 crossref_primary_10_3390_pharmaceutics11090436 crossref_primary_10_1615_CritRevTherDrugCarrierSyst_2023039877 crossref_primary_10_1016_j_ijpharm_2011_01_035 crossref_primary_10_1016_j_colsurfb_2018_06_053 crossref_primary_10_1016_j_ijpharm_2022_121747 crossref_primary_10_1016_j_jconrel_2018_08_016 crossref_primary_10_1021_mp500660m crossref_primary_10_3390_pharmaceutics12050433 crossref_primary_10_3390_molecules21060719 crossref_primary_10_3109_10837450_2013_846374 crossref_primary_10_1002_jps_22603 crossref_primary_10_1016_j_ejps_2017_03_027 crossref_primary_10_1208_s12249_011_9686_y crossref_primary_10_1021_acs_molpharmaceut_8b00122 crossref_primary_10_3390_pharmaceutics12050438 crossref_primary_10_1016_j_ijpharm_2020_119878 crossref_primary_10_1021_acs_cgd_0c00073 crossref_primary_10_1016_j_ejps_2018_01_004 crossref_primary_10_1039_D2SM01189A crossref_primary_10_1016_j_xphs_2018_11_003 crossref_primary_10_1002_jps_22204 crossref_primary_10_1007_s11095_015_1848_2 crossref_primary_10_1016_j_xphs_2017_09_030 crossref_primary_10_1016_j_ejpb_2015_07_011 crossref_primary_10_1021_mp300059z crossref_primary_10_1016_j_jconrel_2018_11_003 crossref_primary_10_3109_03639045_2014_938080 crossref_primary_10_1080_17425247_2021_1844181 crossref_primary_10_1021_acs_molpharmaceut_5b00979 crossref_primary_10_1517_17425247_2014_911728 crossref_primary_10_1016_j_ijpharm_2015_10_015 crossref_primary_10_1002_jps_23099 crossref_primary_10_1021_mp400263d crossref_primary_10_3390_pharmaceutics13020147 crossref_primary_10_1039_D3PM00038A crossref_primary_10_1021_mp400712m crossref_primary_10_1208_s12249_012_9795_2 crossref_primary_10_1021_acs_molpharmaceut_1c00419 crossref_primary_10_1021_acs_molpharmaceut_8b01261 crossref_primary_10_1021_acsami_2c12666 crossref_primary_10_1021_mp400299a crossref_primary_10_1038_s41598_017_02676_2 crossref_primary_10_1039_C0CE00592D crossref_primary_10_1208_s12249_022_02234_8 crossref_primary_10_1016_j_addr_2011_10_009 crossref_primary_10_1016_j_addr_2015_12_019 crossref_primary_10_1016_j_jddst_2019_01_017 crossref_primary_10_1007_s11095_019_2632_5 crossref_primary_10_1021_acs_molpharmaceut_2c00357 crossref_primary_10_1111_jphp_12183 crossref_primary_10_1002_jps_23125 crossref_primary_10_1021_acs_molpharmaceut_1c00481 crossref_primary_10_3390_ph13070147 crossref_primary_10_1007_s11095_009_9970_7 crossref_primary_10_1016_j_addr_2011_07_009 crossref_primary_10_3390_polym16020286 crossref_primary_10_1016_j_chmed_2021_12_004 crossref_primary_10_1021_acs_molpharmaceut_3c00265 crossref_primary_10_1016_j_ijpharm_2020_119086 crossref_primary_10_1016_j_xphs_2018_10_038 crossref_primary_10_4155_tde_14_101 crossref_primary_10_1016_j_jconrel_2022_09_056 crossref_primary_10_1016_j_ijpharm_2023_123440 crossref_primary_10_1021_acs_molpharmaceut_3c00020 crossref_primary_10_1016_j_ijpharm_2010_12_011 crossref_primary_10_1080_10837450_2023_2233595 crossref_primary_10_1007_s40005_017_0361_5 crossref_primary_10_1016_j_ejpb_2016_03_007 crossref_primary_10_1016_j_ejps_2023_106655 crossref_primary_10_1021_mp500412d crossref_primary_10_2174_2667387817666230425135344 crossref_primary_10_1007_s11095_017_2265_5 crossref_primary_10_1016_j_ijpharm_2022_121532 crossref_primary_10_3109_10837450903584936 crossref_primary_10_4155_tde_14_116 crossref_primary_10_1016_j_ijpharm_2021_120964 crossref_primary_10_1016_j_micromeso_2011_12_013 crossref_primary_10_1002_jps_23353 crossref_primary_10_1016_j_ijpharm_2018_11_042 crossref_primary_10_1016_j_ijpharm_2012_12_045 crossref_primary_10_1039_D2RA07019G crossref_primary_10_1016_j_ejps_2020_105636 crossref_primary_10_1016_j_ejps_2020_105514 crossref_primary_10_1016_j_ijpharm_2014_09_010 crossref_primary_10_1002_aic_13724 crossref_primary_10_1016_j_trac_2013_06_002 crossref_primary_10_1016_j_ejpb_2013_01_008 crossref_primary_10_1016_j_ijpharm_2010_05_033 crossref_primary_10_1016_j_ejps_2018_01_014 crossref_primary_10_1016_j_ijpharm_2012_11_001 crossref_primary_10_1021_acs_molpharmaceut_1c00141 crossref_primary_10_1021_acs_jafc_5b03953 crossref_primary_10_1021_acs_molpharmaceut_2c00892 crossref_primary_10_1016_j_ijpharm_2016_10_043 crossref_primary_10_1016_j_ijpharm_2020_119300 crossref_primary_10_3109_10837450_2014_882938 crossref_primary_10_1111_jphp_12488 crossref_primary_10_1007_s12247_012_9127_9 crossref_primary_10_1016_j_ejps_2016_11_023 crossref_primary_10_1248_bpb_b19_00642 crossref_primary_10_1007_s11095_010_0306_4 crossref_primary_10_1021_acs_molpharmaceut_8b00445 crossref_primary_10_3109_10837450_2013_795168 |
Cites_doi | 10.1016/S0939-6411(00)00076-X 10.1002/jps.1090 10.1007/s11095-007-9331-3 10.1002/1520-6017(200008)89:8<1063::AID-JPS11>3.0.CO;2-0 10.1007/s10870-007-9283-9 10.1023/A:1012167410376 10.1021/jp036080l 10.1007/s11095-008-9721-1 10.1016/S0169-409X(01)00098-9 10.1007/s11095-004-1882-y 10.1002/jps.1041 10.1023/A:1018945117471 10.1002/jps.10205 10.1016/j.jcrysgro.2004.02.023 10.1208/pt0802029 10.1063/1.1744688 10.1002/jrs.1139 10.1002/jps.1150 10.1023/A:1022219429708 10.1021/js9601896 10.1007/s11095-007-9420-3 10.1021/JS9704801 10.1248/cpb.50.822 10.1021/js980253e 10.1023/A:1011983606606 10.1002/1520-6017(200103)90:3<371::AID-JPS12>3.0.CO;2-N 10.1002/jps.2600670609 10.1016/S0022-3093(00)00107-1 10.1023/A:1018901325842 10.1002/jps.2600680720 10.1021/js9602711 10.1021/ma062860r 10.1002/jps.2600600902 10.1248/cpb.53.1240 10.1007/s11095-006-9047-9 10.1023/A:1018960405504 10.1002/jps.10308 10.1201/9780203490396 |
ContentType | Journal Article |
Copyright | Copyright © 2009 American Chemical Society |
Copyright_xml | – notice: Copyright © 2009 American Chemical Society |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION |
DOI | 10.1021/mp900050c |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
DocumentTitleAlternate | Moisture-Induced Immiscibility |
EISSN | 1543-8392 |
EndPage | 1505 |
ExternalDocumentID | 10_1021_mp900050c 19634917 c326109689 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | - 123 4.4 53G 55A 5VS 7~N AABXI ABMVS ABUCX ACGFS ACS AEESW AENEX AFEFF ALMA_UNASSIGNED_HOLDINGS AQSVZ BAANH CS3 DU5 EBS ED ED~ EJD F5P GNL H~9 IH9 JG JG~ LG6 P2P RNS ROL UI2 VF5 VG9 W1F X --- -~X ABJNI ABQRX ADHLV AHGAQ CGR CUPRZ CUY CVF ECM EIF GGK IHE NPM AAYXX CITATION |
ID | FETCH-LOGICAL-a380t-59f89736dcf8910059fbf3f379c76094d58bfdfbc810c3eab3efde4b65156c653 |
IEDL.DBID | ACS |
ISSN | 1543-8384 |
IngestDate | Fri Aug 23 03:16:31 EDT 2024 Sat Sep 28 07:56:00 EDT 2024 Thu Aug 27 13:42:20 EDT 2020 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | crystallization Solid dispersion miscibility amorphous moisture |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-a380t-59f89736dcf8910059fbf3f379c76094d58bfdfbc810c3eab3efde4b65156c653 |
PMID | 19634917 |
PageCount | 14 |
ParticipantIDs | crossref_primary_10_1021_mp900050c pubmed_primary_19634917 acs_journals_10_1021_mp900050c |
ProviderPackageCode | JG~ 55A AABXI GNL VF5 7~N VG9 W1F ACS AEESW AFEFF ABMVS ABUCX IH9 BAANH AQSVZ ED~ UI2 |
PublicationCentury | 2000 |
PublicationDate | 2009-10-05 |
PublicationDateYYYYMMDD | 2009-10-05 |
PublicationDate_xml | – month: 10 year: 2009 text: 2009-10-05 day: 05 |
PublicationDecade | 2000 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Molecular pharmaceutics |
PublicationTitleAlternate | Mol. Pharmaceutics |
PublicationYear | 2009 |
Publisher | American Chemical Society |
Publisher_xml | – name: American Chemical Society |
References | Konno H. (ref16/cit16) 2008; 25 Marsac P. J. (ref17/cit17) Hancock B. C. (ref2/cit2) 1997; 86 Vasanthavada M. (ref18/cit18) 2005; 22 He X. R. (ref26/cit26) 2001; 90 Pikal M. J. (ref6/cit6) 1978; 67 Oberholtzer E. R. (ref5/cit5) 1979; 68 Flory P. J. (ref35/cit35) 1953 Gregorowicz J. (ref37/cit37) 2007; 40 (ref40/cit40) 2006 Wang L. A. (ref20/cit20) 2005; 53 Taylor L. S. (ref13/cit13) 2001; 90 Lu Q. (ref22/cit22) 1998; 15 Yalkowsky S. H. (ref31/cit31) 1999 Blassi P. (ref45/cit45) 2007; 8 Saleki-Gerhardt A. (ref12/cit12) 1994; 11 Marsac P. J. (ref15/cit15) 2008; 25 Andronis V. (ref9/cit9) 1997; 86 Yu L. (ref4/cit4) 2001; 48 Six K. (ref23/cit23) 2003; 20 Shamblin S. L. (ref10/cit10) 1999; 16 Yalkowsky S. H. (ref41/cit41) 2003 Liang L. (ref44/cit44) 1998; 87 Tong P. (ref42/cit42) 2001; 90 Shamblin S. L. (ref28/cit28) 1998; 87 Marsac P. J. (ref24/cit24) 2007 Chiou W. L. (ref1/cit1) 1971; 60 Hoffman J. D. (ref32/cit32) 1958; 29 Chan K. L. A. (ref25/cit25) 2004; 35 Marsac P. J. (ref33/cit33) 2009; 26 Taylor L. S. (ref19/cit19) 1997; 14 Gupta M. K. (ref39/cit39) 2003; 92 Actins A. (ref43/cit43) 2008; 38 Di Martino P. (ref30/cit30) 2004; 265 Andronis V. (ref7/cit7) 2000; 271 Zhang J. (ref38/cit38) 2000; 89 Leuner C. (ref3/cit3) 2000; 50 Ford J. L. (ref11/cit11) 1986; 61 Crowley K. J. (ref29/cit29) 2002; 91 Aso Y. (ref14/cit14) 2002; 50 Hancock B. C. (ref8/cit8) 1993; 10 Marsac P. J. (ref21/cit21) 2006; 23 Rumondor A. C. F. (ref27/cit27) 2009 Zhang J. (ref36/cit36) 2001; 90 Marcolli C. (ref34/cit34) 2004; 108 |
References_xml | – volume: 50 start-page: 47 issue: 1 year: 2000 ident: ref3/cit3 publication-title: Eur. J. Pharm. Biopharm. doi: 10.1016/S0939-6411(00)00076-X contributor: fullname: Leuner C. – volume: 90 start-page: 1375 issue: 9 year: 2001 ident: ref36/cit36 publication-title: J. Pharm. Sci. doi: 10.1002/jps.1090 contributor: fullname: Zhang J. – volume: 25 start-page: 969 issue: 4 year: 2008 ident: ref16/cit16 publication-title: Pharm. Res. doi: 10.1007/s11095-007-9331-3 contributor: fullname: Konno H. – volume: 89 start-page: 1063 issue: 8 year: 2000 ident: ref38/cit38 publication-title: J. Pharm. Sci. doi: 10.1002/1520-6017(200008)89:8<1063::AID-JPS11>3.0.CO;2-0 contributor: fullname: Zhang J. – volume-title: Molecular Level Understanding of Polymer Induced Formation and Stabilization of Amorphous API year: 2007 ident: ref24/cit24 contributor: fullname: Marsac P. J. – volume: 38 start-page: 169 issue: 3 year: 2008 ident: ref43/cit43 publication-title: J. Chem. Crystallogr. doi: 10.1007/s10870-007-9283-9 contributor: fullname: Actins A. – volume: 14 start-page: 1691 issue: 12 year: 1997 ident: ref19/cit19 publication-title: Pharm. Res. doi: 10.1023/A:1012167410376 contributor: fullname: Taylor L. S. – volume: 108 start-page: 2216 issue: 12 year: 2004 ident: ref34/cit34 publication-title: J. Phys. Chem. A doi: 10.1021/jp036080l contributor: fullname: Marcolli C. – volume: 26 start-page: 139 issue: 1 year: 2009 ident: ref33/cit33 publication-title: Pharm. Res. doi: 10.1007/s11095-008-9721-1 contributor: fullname: Marsac P. J. – volume: 48 start-page: 27 issue: 1 year: 2001 ident: ref4/cit4 publication-title: Adv. Drug Delivery Rev. doi: 10.1016/S0169-409X(01)00098-9 contributor: fullname: Yu L. – volume: 22 start-page: 440 issue: 3 year: 2005 ident: ref18/cit18 publication-title: Pharm. Res. doi: 10.1007/s11095-004-1882-y contributor: fullname: Vasanthavada M. – ident: ref17/cit17 publication-title: J. Pharm. Sci. contributor: fullname: Marsac P. J. – volume: 90 start-page: 888 issue: 7 year: 2001 ident: ref13/cit13 publication-title: J. Pharm. Sci. doi: 10.1002/jps.1041 contributor: fullname: Taylor L. S. – volume: 11 start-page: 1166 issue: 8 year: 1994 ident: ref12/cit12 publication-title: Pharm. Res. doi: 10.1023/A:1018945117471 contributor: fullname: Saleki-Gerhardt A. – volume: 91 start-page: 2150 issue: 10 year: 2002 ident: ref29/cit29 publication-title: J. Pharm. Sci. doi: 10.1002/jps.10205 contributor: fullname: Crowley K. J. – volume: 61 start-page: 69 year: 1986 ident: ref11/cit11 publication-title: Pharm. Acta Helv. contributor: fullname: Ford J. L. – volume: 265 start-page: 302 issue: 1 year: 2004 ident: ref30/cit30 publication-title: J. Cryst. Growth doi: 10.1016/j.jcrysgro.2004.02.023 contributor: fullname: Di Martino P. – volume: 8 start-page: E1−E8 issue: 2 year: 2007 ident: ref45/cit45 publication-title: AAPS Pharm. Sci. Tech. doi: 10.1208/pt0802029 contributor: fullname: Blassi P. – volume: 29 start-page: 1192 issue: 5 year: 1958 ident: ref32/cit32 publication-title: J. Chem. Phys. doi: 10.1063/1.1744688 contributor: fullname: Hoffman J. D. – volume-title: Principles of Polymer Chemistry year: 1953 ident: ref35/cit35 contributor: fullname: Flory P. J. – volume: 35 start-page: 353 issue: 5 year: 2004 ident: ref25/cit25 publication-title: J. Raman Spectrosc. doi: 10.1002/jrs.1139 contributor: fullname: Chan K. L. A. – volume-title: The Effects of Moisture on Pharmaceutical Amorphous Solid Dispersion Systems year: 2009 ident: ref27/cit27 contributor: fullname: Rumondor A. C. F. – volume: 90 start-page: 1991 issue: 12 year: 2001 ident: ref42/cit42 publication-title: J. Pharm. Sci. doi: 10.1002/jps.1150 contributor: fullname: Tong P. – volume: 20 start-page: 135 issue: 1 year: 2003 ident: ref23/cit23 publication-title: Pharm. Res. doi: 10.1023/A:1022219429708 contributor: fullname: Six K. – volume: 86 start-page: 1 issue: 1 year: 1997 ident: ref2/cit2 publication-title: J. Pharm. Sci. doi: 10.1021/js9601896 contributor: fullname: Hancock B. C. – volume: 25 start-page: 647 issue: 3 year: 2008 ident: ref15/cit15 publication-title: Pharm. Res. doi: 10.1007/s11095-007-9420-3 contributor: fullname: Marsac P. J. – volume: 87 start-page: 694 issue: 6 year: 1998 ident: ref28/cit28 publication-title: J. Pharm. Sci. doi: 10.1021/JS9704801 contributor: fullname: Shamblin S. L. – volume-title: The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals year: 2006 ident: ref40/cit40 – volume: 50 start-page: 822 issue: 6 year: 2002 ident: ref14/cit14 publication-title: Chem. Pharm. Bull. doi: 10.1248/cpb.50.822 contributor: fullname: Aso Y. – volume: 87 start-page: 1496 issue: 12 year: 1998 ident: ref44/cit44 publication-title: J. Pharm. Sci. doi: 10.1021/js980253e contributor: fullname: Liang L. – volume: 15 start-page: 1202 issue: 8 year: 1998 ident: ref22/cit22 publication-title: Pharm. Res. doi: 10.1023/A:1011983606606 contributor: fullname: Lu Q. – volume: 90 start-page: 371 issue: 3 year: 2001 ident: ref26/cit26 publication-title: J. Pharm. Sci. doi: 10.1002/1520-6017(200103)90:3<371::AID-JPS12>3.0.CO;2-N contributor: fullname: He X. R. – volume: 67 start-page: 767 issue: 6 year: 1978 ident: ref6/cit6 publication-title: J. Pharm. Sci. doi: 10.1002/jps.2600670609 contributor: fullname: Pikal M. J. – volume: 271 start-page: 236 issue: 3 year: 2000 ident: ref7/cit7 publication-title: J. Non -Cryst. Solids doi: 10.1016/S0022-3093(00)00107-1 contributor: fullname: Andronis V. – volume: 10 start-page: 1262 issue: 9 year: 1993 ident: ref8/cit8 publication-title: Pharm. Res. doi: 10.1023/A:1018901325842 contributor: fullname: Hancock B. C. – volume: 68 start-page: 863 issue: 7 year: 1979 ident: ref5/cit5 publication-title: J. Pharm. Sci. doi: 10.1002/jps.2600680720 contributor: fullname: Oberholtzer E. R. – volume: 86 start-page: 346 issue: 3 year: 1997 ident: ref9/cit9 publication-title: J. Pharm. Sci. doi: 10.1021/js9602711 contributor: fullname: Andronis V. – volume: 40 start-page: 5966 issue: 16 year: 2007 ident: ref37/cit37 publication-title: Macromolecules doi: 10.1021/ma062860r contributor: fullname: Gregorowicz J. – volume: 60 start-page: 1281 issue: 9 year: 1971 ident: ref1/cit1 publication-title: J. Pharm. Sci. doi: 10.1002/jps.2600600902 contributor: fullname: Chiou W. L. – volume: 53 start-page: 1240 issue: 10 year: 2005 ident: ref20/cit20 publication-title: Chem. Pharm. Bull. doi: 10.1248/cpb.53.1240 contributor: fullname: Wang L. A. – volume: 23 start-page: 2306 issue: 10 year: 2006 ident: ref21/cit21 publication-title: Pharm. Res. doi: 10.1007/s11095-006-9047-9 contributor: fullname: Marsac P. J. – volume: 16 start-page: 1119 issue: 7 year: 1999 ident: ref10/cit10 publication-title: Pharm. Res. doi: 10.1023/A:1018960405504 contributor: fullname: Shamblin S. L. – volume-title: Solubility and Solubilization in Aqueous Media year: 1999 ident: ref31/cit31 contributor: fullname: Yalkowsky S. H. – volume: 92 start-page: 536 issue: 3 year: 2003 ident: ref39/cit39 publication-title: J. Pharm. Sci. doi: 10.1002/jps.10308 contributor: fullname: Gupta M. K. – volume-title: Handbook of Aqueous Solubility Data year: 2003 ident: ref41/cit41 doi: 10.1201/9780203490396 contributor: fullname: Yalkowsky S. H. |
SSID | ssj0024523 |
Score | 2.4149957 |
Snippet | The objective of this study was to investigate the phase behavior of amorphous solid dispersions composed of a hydrophobic drug and a hydrophilic polymer... |
SourceID | crossref pubmed acs |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 1492 |
SubjectTerms | Adsorption Calorimetry, Differential Scanning Crystallization Droperidol - chemistry Drug Delivery Systems Drug Interactions Humidity Hydrophobic and Hydrophilic Interactions Indomethacin - chemistry Ketoprofen - chemistry Nifedipine - chemistry Phase Transition Pimozide - chemistry Povidone - chemistry Spectrophotometry, Infrared Water - chemistry |
Title | Phase Behavior of Poly(vinylpyrrolidone) Containing Amorphous Solid Dispersions in the Presence of Moisture |
URI | http://dx.doi.org/10.1021/mp900050c https://www.ncbi.nlm.nih.gov/pubmed/19634917 |
Volume | 6 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bS8MwFA5uvvji_TIvI6gMhRWbpZf0cezCXpTCJvhWmhsMt3a0q9B_b9J21oGiUCilaQjnpDlfcjjfB8C9iShlwvGMUHBhaA4pw3OkZTALmYRzglym650nU_fljQxHmibn7pcMfg89LVeFrqXJGmC35yqEoPHPYFoT6tmFhpuCAtggmFgb-qDvn-rQw9Kt0LMFIotgMj741zAOwX6FFWG_dO4R2BHRMej4Jdl03oWzunYq7cIO9Gsa6vwEvKvHVMCKADGBsYR-vMgfPuZRvljliZbr4XEkHqFmqCqFImB_GSvDx1kKp_o1HM41k7g-UUvhPIIKLUK_KFhiQnf4HKtZkiXiFLyOR7PBxKikFYwQE3Nt2J4knosdztQd6QpUSSWW2PWY66gdH7cJlVxSRpDJsAgpFpILi2rhdIc5Nj4DzUgN8QJAxJFDmIs8S6iLasZ8RD3X4xZXi3pot0Bb2T6ofo00KLLePRR8GbQFbjduCVYlxcZPjc5Lh9VN1NJhqc3m5V_9X4G9IgVUZP2vQXOdZOIGNFKetYuZ9Ak-BcKD |
link.rule.ids | 315,782,786,2769,27085,27933,27934,56747,56797 |
linkProvider | American Chemical Society |
linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1ZS8QwEA6uPuiL961rEBEFg43pkT6KByseFHYF38rmgsXddmms0H9vklarIIhQKKVpGDJp5kun830AHHmYMS7DGA2lkMhySKE4VD7iPvaoEBRH3NY79_rR0wu9vvmiybG1MMYIbXrSLonfsgvg88nUyVt6vAPmgtCAYAuDrvotr17gpNwMIiCIEup_sgh9f9RGIK5_RKAfWNLFlNul_1izDBYb5Agva1evgBmZrYLjpKaers7goK2k0mfwGCYtKXW1Bl7NpZawoUMsYK5gko-rk_dRVo2nVWHFe0SeyVNo-apq2Qh4OcmNG_JSw769Da9Hllfcfl_TcJRBgx1h4sqXuLQdPuZmzpSFXAfPtzeDqx5qhBbQkFDvDQWxonFEQsHNGdt6VMUUUSSKeRSa_Z8IKFNCMU6xx4kcMiKVkD6zMuohDwOyAWYzY-IWgFjgkPIIx740B7P8-ZjFUSx8YZb4YbANumY80-ZF0anLgV_g9GtAt8Hhp3fSaU248VujzdpvbROzkPhm67nzV_8HYL43eHxIH-6e7nfBgksOuf8B9sDsW1HKfdDRouy6yfUBoPvK8A |
linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3rS8MwEA8-QPzi-zGfQWQoWG1MH8nH4RwTdRSm4LeyvGC4tWNxQv97k7RzDgQRCqU0DUcuyd3ler8fAOc-YozLiHo9KaRnMaQ8GqnA4wHyiRAExdzWO7e7ceeNNO8tTM71tBbGCKFNT9ol8e2qHglVIQygm-HIUVz6fBEsh1FMbbDVuOvOsPVCR-dmvALsEUyCKZLQz0-tFeJ6zgrN-ZPOrrTW_yvRBlirPEjYKFW-CRZktgXqSQlBXVzBl1lFlb6CdZjMwKmLbfBuHrWEFSziGOYKJvmguPjsZ8VgVIwtiY_IM3kJLW5VSR8BG8PcqCOfaNi1r2Gzb_HF7Tmbhv0MGh8SJq6MiUvb4XNu5s5kLHfAa-v-5a7tVYQLXg8T_8MLqSI0xpHg5o5sXapiCiscUx5HJg4UIWFKKMYJ8jmWPYalEjJglk494lGId8FSZkTcBxAJFBEeIxpIczGLo48YjakIhNnqe2ENnJgxTasFo1OXC79F6feA1sDZVEPpqATe-K3RXqm7WROzoQQmBD34q_9TsJI0W-nTQ-fxEKy6HJH7LeAILH2MJ_IYLGoxOXHz6wtiLM1z |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Phase+Behavior+of+Poly%28vinylpyrrolidone%29+Containing+Amorphous+Solid+Dispersions+in+the+Presence+of+Moisture&rft.jtitle=Molecular+pharmaceutics&rft.au=Rumondor%2C+Alfred+C.+F&rft.au=Marsac%2C+Patrick+J&rft.au=Stanford%2C+Lindsay+A&rft.au=Taylor%2C+Lynne+S&rft.date=2009-10-05&rft.pub=American+Chemical+Society&rft.issn=1543-8384&rft.eissn=1543-8392&rft.volume=6&rft.issue=5&rft.spage=1492&rft.epage=1505&rft_id=info:doi/10.1021%2Fmp900050c&rft.externalDocID=c326109689 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1543-8384&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1543-8384&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1543-8384&client=summon |